Some key financial metrics from the recent earnings conference call transcripts include:
- Total reported revenues in the third quarter were $859 million, with a 8% year-over-year growth.
- Non-GAAP earnings per share of $1.44 grew 17% year-over-year.
- Product sales were driven by growth in the U.S., Europe, and the Asia Pacific region, with a 9% increase in volume.
- Soliris revenue was $756 million, with a 3% year-over-year volume growth and an approximately 4% headwind from ALXN1210 and other clinical trial enrollment.
- Strensiq revenue was $87 million with continued momentum from existing patients and new patient additions, but impacted by changes to pricing strategy in the U.S.
- Kanuma achieved revenues of $16 million.
- Non-GAAP operating margin was 45%, benefiting from revenue growth and focus on operating expenses.
- Free cash flow generated over $580 million in the quarter, with approximately $1.5 billion in cash and marketable securities.
- Full-year revenue guidance is expected to be between $3.475 billion to $3.525 billion, representing a 13% total revenue growth year-over-year.
- Total revenue growth would be approximately 17% excluding foreign currency headwinds and the impact of ALXN1210 and other trials on Soliris.
- Non-GAAP EPS guidance is $5.50 to $5.65, representing approximately 21% growth at the mid-point of the range.

These financial metrics highlight the company's revenue growth, earnings per share, product sales, and operating margin, providing a comprehensive overview of the company's financial performance.